TAS-103 (dihydrochloride)

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

TAS-103 dihydrochloride 是一种 DNA 拓扑异构酶 I/II (topoisomerase I/II) 双重抑制剂，可用于癌症研究。

TAS-103 (dihydrochloride) is a novel anticancer agent targeting both topoisomerase (Topo) I and Topo II.

TAS-103 is a dual inhibitor of DNA topoisomerase I/II. TAS-103 (0.1-10 μM) is active on CCRF-CEM cells, with an IC50 value of 5 nM. TAS-103 (0.1 μM) significantly increases levels of topo IIα FITC immunofluorescence in individual CCRF-CEM cells. TAS-103 (0.01-1 μM) is highly cytotoxic to Lewis lung carcinoma (LLC) cells, and Liposomal TAS-103 is almost as active as free TAS-103. TAS-103 inhibits the viability of HeLa cells, with an IC50 of 40 nM. TAS-103 (10 μM) disrupts signal recognition particle (SRP) complex formation, and induces destabilization of SRP14 and SRP19 and its eventual degradation.

TAS-103 (30 mg/kg, i.v.) causes significant tumor growth suppression in mice bearing Lewis lung carcinoma (LLC) cells, without obvious body weight loss, and the liposomal TAS-103 is more active than free TAS-103.

BMS-247615 dihydrochloride

Cell Cycle/DNA Damage

Topoisomerase

topo I/II

——

——

174634-09-4

406.31

C20H21Cl2N3O2

>98% (HPLC)

H2O:50 mg/mL (123.06 mM; Need ultrasonic)

Cl.Cl.CN(C)CCNc1nc2cc(O)ccc2c2-c3ccccc3C(=O)c12

.6-((2-(dimethylamino)ethyl)amino)-3-hydroxy-7H-indeno[21-c]quinolin-7-one dihydrochloride

(-20℃)

With Ice Pack

≥ 2 years